Matches in Wikidata for { <http://www.wikidata.org/entity/Q93704419> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q93704419 description "clinical trial" @default.
- Q93704419 description "ensayo clínico" @default.
- Q93704419 description "ensayu clínicu" @default.
- Q93704419 description "klinisch onderzoek" @default.
- Q93704419 description "клінічне випробування" @default.
- Q93704419 description "կլինիկական փորձարկում" @default.
- Q93704419 description "临床试验" @default.
- Q93704419 name "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 name "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 type Item @default.
- Q93704419 label "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 label "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 prefLabel "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 prefLabel "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer" @default.
- Q93704419 P1050 Q93704419-20C0AD05-8A3C-4F4B-AC17-C5182DF3691C @default.
- Q93704419 P1132 Q93704419-BCEAB03B-450A-46CB-BC33-EBB12F0B0203 @default.
- Q93704419 P1476 Q93704419-A6F15261-FF01-4A12-A387-E2D14708613B @default.
- Q93704419 P17 Q93704419-0A3F744F-A3D2-41BF-A762-8B0338F2ADF4 @default.
- Q93704419 P2899 Q93704419-902E9DFB-D621-4385-B11E-99AAE7C272AC @default.
- Q93704419 P3098 Q93704419-7FF3B6AF-2562-4A55-AB7A-E202B92EF5C3 @default.
- Q93704419 P31 Q93704419-6A1F1081-52C8-429B-8F80-5DC39E24AFCE @default.
- Q93704419 P4844 Q93704419-07F269B5-29FC-4552-949A-6AA654210B13 @default.
- Q93704419 P4844 Q93704419-36722F8D-E299-4BC4-B0BA-EEDC5A3A2EB4 @default.
- Q93704419 P4844 Q93704419-87D05082-C03B-4136-AB62-0EC688F13121 @default.
- Q93704419 P4844 Q93704419-ACB79589-3866-4798-95C1-AF63E3F8C418 @default.
- Q93704419 P580 Q93704419-4B0FD1E8-13FB-4BC8-B5EA-23F42CA97CAE @default.
- Q93704419 P582 Q93704419-AC1C25C1-3906-4213-8CF5-A9E29EA9BE70 @default.
- Q93704419 P6099 Q93704419-54856977-76A5-4C65-9708-DA3483D691B7 @default.
- Q93704419 P6099 Q93704419-8DE35E21-E919-4C3F-A4D8-0C8C9757EED3 @default.
- Q93704419 P767 Q93704419-A2950C21-B86B-42F4-B5DD-6B0CCC5568E0 @default.
- Q93704419 P8005 Q93704419-BB4F409C-BC73-493B-9D6D-09494323209A @default.
- Q93704419 P8363 Q93704419-E9B8645A-AE11-4935-AC8E-8551382DB211 @default.
- Q93704419 P859 Q93704419-A02649B2-8F98-4852-BD11-C2823E24F472 @default.
- Q93704419 P1050 Q33525 @default.
- Q93704419 P1132 "+15" @default.
- Q93704419 P1476 "A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma" @default.
- Q93704419 P17 Q30 @default.
- Q93704419 P2899 "+12" @default.
- Q93704419 P3098 "NCT04380545" @default.
- Q93704419 P31 Q30612 @default.
- Q93704419 P4844 Q188269 @default.
- Q93704419 P4844 Q20801720 @default.
- Q93704419 P4844 Q238512 @default.
- Q93704419 P4844 Q7041828 @default.
- Q93704419 P580 "2020-09-01T00:00:00Z" @default.
- Q93704419 P582 "2021-07-20T00:00:00Z" @default.
- Q93704419 P6099 Q42824440 @default.
- Q93704419 P6099 Q5452194 @default.
- Q93704419 P767 Q664846 @default.
- Q93704419 P8005 Q76649614 @default.
- Q93704419 P8363 Q78089383 @default.
- Q93704419 P859 Q1525831 @default.